A randomized controlled trial on optimal administration frequency of continuous erythropoietin receptor activator in hemodialysis patients with renal anemia.
- Conditions
- renal anemia
- Registration Number
- JPRN-jRCTs031180030
- Lead Sponsor
- Toya Yoshiyuki
- Brief Summary
In hemodialysis patients, we did not find significant difference in CERA dosage, Hb maintenance and iron metabolism in QW group compared with Q2W group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
(1) Outpatients in maintenance hemodialysis with renal anemia
(2) Patients over 20 years of age
(3) Patients with a hemodialysis history of more than 12 weeks
(4) Patients with a history of receiving erythropoiesis stimulating agents for more than 12 weeks
(5) Patients who was obtained written informed consent regarding the participation of this study
(1)Heart failure above NYHA 3 degrees.
(2)Poorly controlled high blood pressure (diastolic blood pressure before dialysis 110 mmHg or more).
(3)Chemotherapy or radiotherapy for malignancy within 24 weeks.
(4)Red blood cell transfusion within 12 weeks.
(5)Major surgery within 12 weeks (thoracotomy, laparotomy etc.)
(6)Patients who are pregnant.
(7)Other patients judged inappropriate for the study
by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The dose of epoetin beta pegol during 12 weeks of comparison period.
- Secondary Outcome Measures
Name Time Method (1)hepcidin<br>(2)ferittin and TSAT<br>(3)Ret-Hb and Ret-He<br>(4)Hb<br>(5)ERI<br>(6)the iron administration during comparison period.<br>(7) Presence of discontinuation of protocol treatment due to red blood cell transfusion or ESA type change after starting of comparison period